Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
INCY
Incyte Corp.
$65.06
Chart
$56.8 (+14.54%)
$70.79 (-8.09%)
$72.53 (-10.30%)
$62.11 (+4.75%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-2.92%
-2.08%
-3.34%
+9.79%
-19.01%
INCY
Incyte Corp.
Current Price
$65.06
Login to view Incyte Corp. (INCY) recommendation from the last 90 days from financial news and social media.
Chart
$56.8 (+14.54%)
$70.79 (-8.09%)
$72.53 (-10.30%)
$62.11 (+4.75%)
INCY Latest Headlines
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15 Companies and 20 Therapies | DelveInsight. Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15 Companies and 20 Therapies |. DelveInsightThe liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies including immunotherapies and targeted treatments. Increased R&.D investment. Emerging markets are also contributing throug
Tue May 27, 2025
Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15 Companies and 20 Therapies | DelveInsight. Liposarcoma Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 15 Companies and 20 Therapies |. DelveInsightThe liposarcoma treatment market is driven by a rising global disease burden and growing demand for innovative therapies including immunotherapies and targeted treatments. Increased R&.D investment. Emerging markets are also contributing throug
Tue May 27, 2025
Tuesday Sector Leaders: Healthcare Utilities. Looking at the sectors faring best as of midday Tuesday shares of Healthcare companies are outperforming other sectors higher by 0.5%. Within that group Moderna Inc (Symbol: MRNA) and Incyte Corporation (Symbol: INCY) are two large stocks leading the way showing a gain of 8.
Tue May 20, 2025
EDSA: Advancing EB06 for the Treatment of Vitiligo. By Business UpdateAdvancing EB06 for Treating VitiligoEdesa Biotech Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color with non-segmental vitiligo being characterized by patches appearing on both sides of the body. It is caused when pigment-producing cells (melanocytes)
Mon May 19, 2025
EDSA: Advancing EB06 for the Treatment of Vitiligo. By Business UpdateAdvancing EB06 for Treating VitiligoEdesa Biotech Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color with non-segmental vitiligo being characterized by patches appearing on both sides of the body. It is caused when pigment-producing cells (melanocytes)
Mon May 19, 2025
EDSA: Advancing EB06 for the Treatment of Vitiligo. By Business UpdateAdvancing EB06 for Treating VitiligoEdesa Biotech Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color with non-segmental vitiligo being characterized by patches appearing on both sides of the body. It is caused when pigment-producing cells (melanocytes)
Mon May 19, 2025
EDSA: Advancing EB06 for the Treatment of Vitiligo. By Business UpdateAdvancing EB06 for Treating VitiligoEdesa Biotech Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color with non-segmental vitiligo being characterized by patches appearing on both sides of the body. It is caused when pigment-producing cells (melanocytes)
Mon May 19, 2025
EDSA: Advancing EB06 for the Treatment of Vitiligo. By Business UpdateAdvancing EB06 for Treating VitiligoEdesa Biotech Inc. (NASDAQ:EDSA) is planning for a Phase 2 study of its anti-CXCL10 monoclonal antibody for the treatment of moderate-to-severe non-segmental vitiligo patients. Vitiligo is a disease that causes areas of the skin to lose color with non-segmental vitiligo being characterized by patches appearing on both sides of the body. It is caused when pigment-producing cells (melanocytes)
Mon May 19, 2025
Incyte gets expanded FDA approval for Zynyz in anal cancer.
Thu May 15, 2025
Incyte gets expanded FDA approval for Zynyz in anal cancer.
Thu May 15, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
INCY Stock trends
INCY Stock performance
INCY Stock analysis
INCY investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
